These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20000124)

  • 1. [Biosensor analysis of interaction of potential dimerization inhibitors with HIV-1 protease].
    Ershov PV; Gnedenko OV; Mol'nar AA; Lisitsa AV; Ivanov AS; Archakov AI
    Biomed Khim; 2009; 55(4):462-78. PubMed ID: 20000124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triterpenes as potential dimerization inhibitors of HIV-1 protease.
    Quéré L; Wenger T; Schramm HJ
    Biochem Biophys Res Commun; 1996 Oct; 227(2):484-8. PubMed ID: 8967903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thermodynamic analysis of dimerization inhibitors binding to HIV protease monomers].
    Ershov PV; Gnedenko OV; Mol'nar AA; Lisitsa AV; Ivanov AS; Archakov AI
    Biomed Khim; 2012; 58(1):43-9. PubMed ID: 22642151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.
    Bowman MJ; Chmielewski J
    Biopolymers; 2002; 66(2):126-33. PubMed ID: 12325162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of low molecular weight HIV-1 protease dimerization inhibitors.
    Hwang YS; Chmielewski J
    J Med Chem; 2005 Mar; 48(6):2239-42. PubMed ID: 15771466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
    Shuman CF; Vrang L; Danielson UH
    J Med Chem; 2004 Nov; 47(24):5953-61. PubMed ID: 15537350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
    Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical protonation states in the active site of HIV-1 protease: a computational study.
    Czodrowski P; Sotriffer CA; Klebe G
    J Chem Inf Model; 2007; 47(4):1590-8. PubMed ID: 17503762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel screening and activity profiling with HIV protease inhibitor pharmacophore models.
    Steindl TM; Schuster D; Laggner C; Chuang K; Hoffmann RD; Langer T
    J Chem Inf Model; 2007; 47(2):563-71. PubMed ID: 17381173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
    Sperka T; Pitlik J; Bagossi P; Tözsér J
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
    Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
    J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization.
    Dufau L; Marques Ressurreição AS; Fanelli R; Kihal N; Vidu A; Milcent T; Soulier JL; Rodrigo J; Desvergne A; Leblanc K; Bernadat G; Crousse B; Reboud-Ravaux M; Ongeri S
    J Med Chem; 2012 Aug; 55(15):6762-75. PubMed ID: 22800535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization.
    Bannwarth L; Kessler A; Pèthe S; Collinet B; Merabet N; Boggetto N; Sicsic S; Reboud-Ravaux M; Ongeri S
    J Med Chem; 2006 Jul; 49(15):4657-64. PubMed ID: 16854071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational proteomics analysis of binding mechanisms and molecular signatures of the HIV-1 protease drugs.
    Verkhivker G
    Artif Intell Med; 2009; 45(2-3):197-206. PubMed ID: 18926674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling.
    Frutos S; Rodriguez-Mias RA; Madurga S; Collinet B; Reboud-Ravaux M; Ludevid D; Giralt E
    Biopolymers; 2007; 88(2):164-73. PubMed ID: 17236209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket.
    Damm KL; Ung PM; Quintero JJ; Gestwicki JE; Carlson HA
    Biopolymers; 2008 Aug; 89(8):643-52. PubMed ID: 18381626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching between allosteric and dimerization inhibition of HIV-1 protease.
    Bowman MJ; Byrne S; Chmielewski J
    Chem Biol; 2005 Apr; 12(4):439-44. PubMed ID: 15850980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model.
    Wang W; Kollman PA
    J Mol Biol; 2000 Nov; 303(4):567-82. PubMed ID: 11054292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology.
    Markgren PO; Hämäläinen M; Danielson UH
    Anal Biochem; 1998 Dec; 265(2):340-50. PubMed ID: 9882412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.